Belgium Biotechnology & Medical Research

Agomab Therapeutics NV (AGMB)

Ticker: AGMB Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Agomab Therapeutics NV. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
368.09
Quantity 23,967 +8.7%
Value US$180,264
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
86.33
Quantity 1,337 -20.4%
Value US$4,580,667
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
468.19
Quantity 34,367 +2.1%
Value US$1,201,507
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
8.90
Quantity 1,000 +25.0%
Value US$100,000
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
8.86
Quantity 1,000 +33.3%
Value US$100,000
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
8.90
Quantity 5,000 +50.0%
Value US$44,500
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
8.70
Quantity 5,000 +100.0%
Value US$43,500
Kemula Pierre Thadee Victor Chief Financial Officer Officer
Transaction date
Purchase
Price
8.67
Quantity 3,000 New position
Value US$26,010
Knotnerus Tim Jasper Chief Executive Officer Executive Director
Transaction date
Purchase
Price
8.70
Quantity 5,000 +29.7%
Value US$43,500
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
8.57
Quantity 5,000 New position
Value US$42,850
Knotnerus Tim Jasper Chief Executive Officer Executive Director
Transaction date
Purchase
Price
8.48
Quantity 6,000 +55.4%
Value US$50,880
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-11-06 2026-11-05 B Purchase
2.1
Epstein David R
Non-Executive Director
23,967 +8.7%
368.09
US$180,264 		23,967 +8.7% 368.09 US$180,264
2026-11-06 2026-11-05 B Purchase
2.1
Epstein David R
Non-Executive Director
1,337 -20.4%
86.33
US$4,580,667 		1,337 -20.4% 86.33 US$4,580,667
2026-11-06 2026-11-05 B Purchase
2.1
Epstein David R
Non-Executive Director
34,367 +2.1%
468.19
US$1,201,507 		34,367 +2.1% 468.19 US$1,201,507
2026-10-22 2026-10-21 B Purchase
2.1
Epstein David R
Non-Executive Director
1,000 +25.0%
8.90
US$100,000 		1,000 +25.0% 8.90 US$100,000
2026-10-22 2026-10-21 B Purchase
2.1
Epstein David R
Non-Executive Director
1,000 +33.3%
8.86
US$100,000 		1,000 +33.3% 8.86 US$100,000
2026-10-09 2026-10-08 B Purchase
2.1
Epstein David R
Non-Executive Director
5,000 +50.0%
8.90
US$44,500 		5,000 +50.0% 8.90 US$44,500
2026-10-07 2026-10-06 B Purchase
2.1
Epstein David R
Non-Executive Director
5,000 +100.0%
8.70
US$43,500 		5,000 +100.0% 8.70 US$43,500
2026-10-07 2026-10-06 B Purchase
Kemula Pierre Thadee Victor

Chief Financial Officer

Officer
2,000 +25.0%
8.54
US$17,080 		2,000 +25.0% 8.54 US$17,080
2026-10-07 2026-10-06 B Purchase
Kemula Pierre Thadee Victor

Chief Financial Officer

Officer
5,000 +166.7%
8.57
US$42,850 		5,000 +166.7% 8.57 US$42,850
2026-10-07 2026-10-06 B Purchase
Kemula Pierre Thadee Victor

Chief Financial Officer

Officer
3,000 New position
8.67
US$26,010 		3,000 New position 8.67 US$26,010
2026-10-07 2026-10-06 B Purchase
Knotnerus Tim Jasper

Chief Executive Officer

Executive Director
5,000 +29.7%
8.70
US$43,500 		5,000 +29.7% 8.70 US$43,500
2026-10-07 2026-10-05 B Purchase
2.1
Epstein David R
Non-Executive Director
5,000 New position
8.57
US$42,850 		5,000 New position 8.57 US$42,850
2026-10-07 2026-10-05 B Purchase
Knotnerus Tim Jasper

Chief Executive Officer

Executive Director
6,000 +55.4%
8.48
US$50,880 		6,000 +55.4% 8.48 US$50,880
Explore more

More insider trading research around Agomab Therapeutics NV

More insider trades in Belgium
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in Europe